bpc-157 clinical trial bpc157 #peptide #unapproved | Mark Willis bpc 157 clinical trial humans

A broader 2020 review by Sikiric and colleagues in Gut and Liver frames the compound's proposed GI activity within Robert's cytoprotection and organoprotection model the longstanding physiological framework describing how the gastric mucosa protects itself against injury

That is incomplete programming

Over time, studies broadened into musculoskeletal, vascular, and dermal systems, where BPC-157 consistently demonstrated properties of interest in the context of tissue regeneration and biological resilience

[DOI: 10.1371/journal.pmed.1000100] [DOI] [PMC free article] [PubMed] [Google Scholar] Lindenbaum 1994 Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH

Remain cautious of marketing that promises cures or uses pseudoscience